Top Page
Elekta AB
(LSE:EKTA.B)
Elekta AB (EKTA.B) vs. iShares MSCI Sweden ETF (EWD)
Elekta AB Business Overview & Revenue Model
Elekta AB Financial Statement Overview
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 18.02B | 18.12B | 16.87B | 14.55B | 13.76B |
| Gross Profit | 6.75B | 6.78B | 6.35B | 5.44B | 5.61B |
| EBITDA | 2.19B | 3.29B | 2.57B | 2.74B | 3.13B |
| Net Income | 237.00M | 1.30B | 943.00M | 1.15B | 1.25B |
Balance Sheet | |||||
| Total Assets | 28.98B | 31.41B | 29.61B | 26.30B | 24.84B |
| Cash, Cash Equivalents and Short-Term Investments | 2.96B | 2.78B | 3.27B | 3.07B | 4.40B |
| Total Debt | 7.57B | 7.25B | 6.67B | 5.70B | 6.24B |
| Total Liabilities | 20.13B | 20.63B | 19.88B | 17.39B | 16.65B |
| Stockholders Equity | 8.80B | 10.77B | 9.73B | 8.91B | 8.20B |
Cash Flow | |||||
| Free Cash Flow | 1.06B | 817.00M | 400.00M | 450.00M | 1.71B |
| Operating Cash Flow | 2.63B | 2.46B | 1.96B | 1.86B | 2.55B |
| Investing Cash Flow | -1.67B | -1.92B | -1.61B | -1.65B | -613.00M |
| Financing Cash Flow | -607.00M | -1.10B | -129.00M | -1.73B | -3.60B |
Elekta AB Technical Analysis
Elekta AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | kr19.03B | 80.28 | 2.43% | 4.82% | -0.57% | -81.80% | |
52 Neutral | $7.65B | 0.16 | -63.14% | 2.08% | 16.38% | 0.82% | |
| ― | €108.43M | 45.50 | 7.87% | ― | ― | ― | |
| ― | €80.15M | ― | -19.17% | ― | ― | ― | |
| ― | €35.30M | ― | -88.97% | ― | ― | ― | |
| ― | €6.01M | ― | ― | ― | ― | ||
| ― | €146.43M | ― | -5.40% | ― | ― | ― |
Elekta AB Corporate Events
Elekta has received U.S. FDA 510(k) clearance for its Gamma Knife radiosurgery system to treat refractory, drug-resistant mesial temporal lobe epilepsy (MTLE) in adults. This clearance allows U.S. providers to offer a non-invasive, precision treatment option for epilepsy, potentially improving patient outcomes and optimizing resource utilization. The Gamma Knife system, originally developed for functional indications like epilepsy, has been a non-invasive alternative for nearly two million patients globally, sparing healthy brain tissue and critical structures.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
Elekta AB’s annual report for 2024/25 highlights its commitment to advancing cancer care through innovation and collaboration. The report emphasizes the company’s dedication to setting new standards in treatment, reflecting its strategic milestones and sustainability efforts. This announcement underscores Elekta’s role in the healthcare sector, aiming to make a significant impact on cancer treatment and patient lives.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
Elekta’s Nomination Committee has proposed the reelection of several board members and the election of Jan De Witte as a new director for the upcoming term. Jan De Witte brings extensive leadership experience from the global technology and life science industries, which could enhance Elekta’s strategic direction and industry positioning.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
Elekta’s Investor Update in Stockholm showcased its innovative portfolio and strategic growth plans, including restoring gross margin and achieving a 14% EBIT margin. The company highlighted its proactive order review, resulting in a SEK 4.9 billion cancellation, and discussed the positive market reception of its latest products, emphasizing the importance of adaptive radiation therapy in improving clinical outcomes.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
Elekta has appointed Jakob Just-Bomholt as its new President and CEO, effective September 1, 2025. With a strong background in international leadership and innovation, Just-Bomholt is expected to drive Elekta’s growth and global expansion, enhancing its market position and delivering value to stakeholders, including shareholders, customers, and cancer patients worldwide.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
Elekta has acquired assets from its distributor in Croatia, a strategic move to enhance its market position and improve cancer treatment capabilities in the region. This acquisition will allow Elekta to establish a direct presence in Croatia, including an office in Zagreb and the hiring of additional staff, which is expected to positively impact patient care by providing access to advanced cancer treatment technologies. The Croatian Ministry of Health’s order for Elekta’s equipment will address the country’s shortage of radiotherapy units, aligning with Croatia’s National Cancer Plan.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK63.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
Elekta AB reported a 6% increase in net sales for the fourth quarter of 2024/25 at constant exchange rates, driven by strong performance in Europe and APAC, and a 3% increase in reported sales. The company achieved its best fourth-quarter gross margin in five years at 40.3%, supported by price increases, product launches, and a solid performance of its Elekta Evo linear accelerator and Elekta ONE software suite. Despite a non-cash impairment of SEK 1,064 M due to discontinued R&D projects, Elekta maintained a strong book-to-bill ratio and improved cash flow. The company expects continued sales growth and margin improvements, aiming to reach pre-pandemic levels, while its products have received positive feedback from healthcare providers.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK67.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
Elekta has announced a presentation for its fiscal year 2024/25, scheduled for May 28, where the company’s Acting President and CEO, Jonas Bolander, along with CFO Tobias Hägglöv, will discuss the company’s development. The event, which includes a live webcast and Q&A session, reflects Elekta’s commitment to transparency and engagement with analysts and investors, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK67.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.